Ascendia

  MARKET NEWS

Cullinan Oncology Announces FDA Clearance of INDA for Novel Fusion Protein Harnessing IL-2 & IL-12 Cytokines
Kala Pharmaceuticals Announces Positive Safety Update From Cohort 1 of Phase 2b Clinical Trial
Macomics & Ono Pharmaceutical Partner to Discover & Develop Macrophage-Targeting Antibody Therapy for Cancer Treatment
Harm Reduction Therapeutics & Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray to Reverse Opioid Overdoses
Hovione & Laxxon Medical Establish Agreement for cGMP Production of 3D Screen-Printed Pharmaceutical Applications
Visus Therapeutics Completes Enrollment in Phase 3 Clinical Trial for the Treatment of Presbyopia

  FEATURED EDITORIAL

  COMPANY PROFILE

LATITUDE Pharmaceuticals is a leading-edge CDMO that provides innovative drug formulation development services and GMP manufacturing for early phase clinical trials to the human and animal health industries. Founded in 2003, we have completed more than 1,000 client projects and have established a reputation for successfully formulating highly insoluble compounds – the most significant cause of drug development failure. LATITUDE’s formulation scientists overcome the challenges of difficult compounds, and are the foundation of LATITUDE’s reputation for creative approaches, reliability, transparency, rapid turnaround, and client satisfaction. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cyclerion Therapeutics Receives Orphan Drug Designation for the Treatment of Mitochondrial Diseases

Cyclerion Therapeutics Receives Orphan Drug Designation for the Treatment of Mitochondrial Diseases

Cyclerion Therapeutics, Inc. recently announced the US FDA has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases. Zagociguat is the first….

Jounce Therapeutics to be Acquired by Concentra Biosciences

Jounce Therapeutics to be Acquired by Concentra Biosciences

Jounce Therapeutics, Inc. recently announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (Concentra) will acquire Jounce for $1.85 in cash per share plus….

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Arch Biopartners Inc. recently announced it is receiving advisory services and up to $4 million in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the….

Woodstock Sterile Solutions Completes Analytical Lab Expansion, Becomes One-Stop Shop CDMO

Woodstock Sterile Solutions Completes Analytical Lab Expansion, Becomes One-Stop Shop CDMO

Woodstock Sterile Solutions has recently completed an expansion of its quality control analytical laboratory at its production facility in Woodstock, IL. The larger laboratory accommodates…

  WHITEPAPERS & WEBINARS

WEBINAR - Step Into the Future of Therapeutic Antibody Discovery

WEBINAR - Step Into the Future of Therapeutic Antibody Discovery

Join us to hear about our new biotherapeutic antibody discovery service — the Pioneer Platform, and how it can help you find your next lead candidate.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.

Click here to …

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*

Summary

The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 5 – Inhalation Delivery
April 12 – Formulation Development